Brazil Cannabis Import Regulations for Canadian LPs in 2026: What You Need to Know

RDC 327/2019 is the foundation of Brazil's regulated cannabis import framework. It governs the conditions under which cannabis products, including dried flower, cannabis oil, and extracts, can be imported by ANVISA-authorised companies. Before this resolution, importation was possible only under a compassionate use provision, which was slower and less commercially reliable. RDC 327/2019 established a product registration and import authorisation pathway that, while not identical to the German or Australian models, is structured and repeatable.

The key structural difference for Canadian LPs is that ANVISA does not audit foreign facilities directly in most cases. Instead, it reviews documentation submitted by the Brazilian importer on behalf of the foreign supplier. That means the LP must produce a complete, audit-ready documentation package. ANVISA's review criteria mirror the requirements of its Boas Práticas de Fabricação (BPF) standard, which is derived from the WHO GMP guidelines. A Canadian LP operating under Health Canada GPP is generally in a strong position, but the dossier must be translated into Portuguese and presented in the format ANVISA expects.

What ANVISA reviewers look for from a foreign LP's documentation package:

• A valid GMP certificate issued by the competent national authority (Health Canada in Canada's case)
• A site master file describing the manufacturing facility, quality systems, and batch release procedures
• Product dossiers including composition, specifications, and validated analytical methods
• Certificates of Analysis from ISO/IEC 17025-accredited laboratories covering cannabinoid potency, microbials, heavy metals, pesticide residues, and moisture
• Stability data demonstrating product performance over the proposed shelf life

For guidance on interpreting the testing documentation a Brazilian importer will request, see How to Read a Cannabis COA: A B2B Buyer's Guide.

Before any cannabis leaves Canada for Brazil, the LP must satisfy two regulatory bodies: Health Canada on the Canadian side, and ANVISA on the Brazilian side. The Cannabis Act requires an LP to hold export authorisation as a condition of its licence before any export activity can begin. Export authorisation is a standing licence amendment, not a per-shipment approval. Once it's in place, the LP applies to Health Canada for an export permit for each individual shipment.

The per-shipment export permit process has a specific requirement when shipping to Brazil: Health Canada requires proof that Brazil has issued an import certificate confirming the shipment complies with the Single Convention on Narcotic Drugs. This means the timeline runs as follows:

• The Brazilian importer obtains its import authorisation from ANVISA (covering the supplier-product combination)
• For each shipment, the Brazilian importer applies to ANVISA for a narcotic import permit
• ANVISA issues the import certificate
• The Canadian LP submits its Health Canada export permit application, attaching the Brazilian import certificate
• Health Canada issues the export permit, typically within five to ten business days of a complete application

For a detailed walkthrough of Health Canada's export permit application process, see The Health Canada Cannabis Export Permit Process. Coordinating this sequencing with the Brazilian importer in advance is one of the most practical things a Canadian LP can do to avoid shipment delays. The Canadian LP cannot obtain its export permit until the Brazilian certificate exists, so the two entities must work in close step.

Canadian LPs preparing for this kind of documentation-intensive review will find our GPP Audit Preparation guide and our EU-GMP vs Health Canada GMP comparison useful references. ANVISA's documentation expectations are thorough, and Canadian LPs who have not previously exported to Brazil often underestimate the preparation required. BPF is substantively equivalent to WHO GMP, and the review process evaluates whether your quality systems would pass a full facility audit. ANVISA conducts this assessment through documents rather than an on-site inspection in the first instance, which makes the quality of the dossier the primary determinant of success.

GMP certificate and scope

Health Canada issues GMP certificates to Licensed Producers operating under the Cannabis Regulations, confirming GPP compliance. ANVISA reviewers will assess whether the scope of the certificate covers the specific product type being imported. A certificate scoped to dried flower must be present for a dried flower import. If the LP holds EU-GMP certification, including that alongside the Health Canada GMP certificate significantly strengthens the dossier, as ANVISA auditors have established familiarity with the EU-GMP framework and its Qualified Person requirement.

COA standards for the Brazilian channel

Certificate of Analysis requirements for Brazil are stricter in scope than many European markets. ANVISA expects testing for a wider panel of contaminants, and the laboratory must hold ISO/IEC 17025 accreditation. Specific panels ANVISA review requires:

• Cannabinoid profile (total THC, total CBD, and full minor cannabinoid quantification)
• Terpene profile (ANVISA increasingly expects this for product classification)
• Microbial contamination (TAMC, TYMC, E. coli, Salmonella, Staphylococcus aureus, Pseudomonas aeruginosa)
• Heavy metals (lead, cadmium, arsenic, mercury)
• Pesticide residue (consistent with Codex Alimentarius maximum residue limits)
• Moisture and water activity
• Mycotoxins (aflatoxins and ochratoxin A at minimum)

A COA that covers this full panel, signed by an accredited laboratory, provides the evidentiary foundation ANVISA reviewers rely on. Canadian LPs who already commission broad-panel testing for EU or Australian supply are typically well-positioned.

Unlike Germany, where an LP can sometimes deal with pharmacy distributors directly, Brazil's import channel runs almost entirely through licensed importing companies, which are often pharmaceutical distributors or compounding pharmacy networks that hold the ANVISA import authorisation. The LP's commercial relationship is with that importer, and the importer submits everything to ANVISA on the LP's behalf.

This structure has practical implications for how a Canadian LP approaches market entry:

Due diligence on potential importers

Not all Brazilian importers are equally equipped to manage the ANVISA process or to maintain the cold-chain and storage standards that dried cannabis flower requires. The vetting criteria closely mirror what experienced global buyers apply to any LP supplier, a pattern covered in our guide on how to vet a Canadian cannabis LP. Before signing a supply agreement, you should confirm that the importer:

• Holds a current ANVISA operating licence for cannabis product importation
• Has a documented track record of successful prior cannabis import authorisations
• Operates temperature-controlled and humidity-controlled storage that meets the LP's stability data requirements
• Has an internal regulatory affairs team capable of preparing and managing ANVISA dossier submissions

Supply agreement terms that protect both parties

Because the ANVISA import authorisation is product-specific and supplier-specific, the supply agreement should address what happens if ANVISA requests additional documentation, requests a facility inspection, or raises a deficiency query mid-review. The agreement should allocate clear responsibility for dossier preparation costs, translation costs, and response timelines. Canadian LPs who have managed EU-GMP dossiers will recognise the general pattern, though the ANVISA-specific requirements differ in structure.

Pricing agreements should account for the longer lead time inherent in the Brazilian import cycle. Unlike spot-market transactions, each Brazil shipment requires advance permit coordination, so volume commitments and rolling forecasts benefit both parties in this channel.

AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain ISO/IEC 17025-certified batch testing, full traceability records, and the GMP documentation that Brazilian importers need for a successful ANVISA dossier submission. If you're building supply relationships for the Brazilian medical channel, contact us to discuss specifications and capacity.

Does Brazil allow imports of cannabis flower from Canada?

Yes. Under ANVISA RDC 327/2019, Brazilian importers can apply for authorisation to import cannabis products, including dried flower for pharmaceutical compounding, from foreign suppliers who meet ANVISA's GMP documentation requirements. A Canadian LP with a Health Canada Standard Cultivation licence and export authorisation under the Cannabis Act is eligible to supply, but must produce GMP documentation that ANVISA accepts.

What GMP standard does ANVISA require for cannabis imports?

ANVISA applies its own Boas Práticas de Fabricação (BPF) standard, which is closely aligned with the WHO GMP model. Canadian LPs operating under Health Canada Good Production Practices will need to produce a GMP certificate, a site master file, and batch documentation that satisfies ANVISA's review criteria. EU-GMP certification significantly strengthens the application, as ANVISA auditors are familiar with the EU framework, but it is not the only route.

Who holds the import licence in Brazil, the Canadian LP or the Brazilian company?

Import authorisation is issued by ANVISA to the Brazilian importer or compounding pharmacy, not the foreign supplier. As the Canadian LP, your role is to provide the regulatory documentation (GMP certificate, COAs, product dossier) that allows your Brazilian partner to complete its ANVISA import application. LPs do not apply to ANVISA directly and cannot hold the import authorisation themselves.

How long does ANVISA's import authorisation process take?

Processing times vary depending on documentation completeness and ANVISA workload. In 2026, Brazilian importers report average review times of three to six months from application submission to authorisation. Incomplete dossiers are the most common cause of delays. Canadian LPs who prepare the full documentation package in advance help their Brazilian partners meet ANVISA's standards on the first submission.

Does a Canadian LP need a separate Health Canada permit to export to Brazil?

Yes. Under the Cannabis Act, a Canadian LP must hold export authorisation and obtain a per-shipment export permit from Health Canada for each consignment. Brazil must confirm that the importation complies with the Single Convention on Narcotic Drugs, which requires an import certificate from the Brazilian authority before Health Canada issues the export permit. The LP coordinates this permit exchange with its Brazilian importer.